Hugel to Develop Next-generation Type E Botulinum Toxin Product

May 9, 2024
Botox glabellar injection (drawn)

Hugel has started its development of new botulinum toxin products using a botulinum toxin type that has a faster onset and shorter duration of effect, the aesthetics firm said.

According to Hugel, botulinum neurotoxins that are currently used for therapeutic and cosmetic applications have been botulinum neurotoxin type A and B. The onset of action of botulinum toxin A, which is most widely used for cosmetic applications, ranges from three to seven days, while its therapeutic effect usually lasts around three six months.

On the other hand, the onset of botulinum neurotoxin type E’s clinical effect is within 24 hours, with a duration ranging from two to four weeks.

Read more at The Korea Herald >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Bill Regulating Indiana Med Spas Has Passed: What You Need to Know and Why Collective Advocacy Matters
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor